Tissue-Specific Effects of Chlorpyrifos on Carboxylesterase and Cholinesterase Activity in Adult Rats: An in Vitro and in Vivo Study. Chanda, S. M, Mortensen, S. R., Moser, V. C, and Padilla, S. (1997) . Fundam. Appl. Toxicol. 38, [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] Organophosphate (OP) pesticides can bind to carboxylesterase (CaE), which may lower the concentration of OPs at the target site enzyme, acetylcholinesterase (ChE). It is unclear from the literature whether it is the CaE's affinity for the OP and/or the number of CaE molecules which is the dominant factor in determining the protective potential of CaE. We undertook a detailed, in vitro and in vivo survey of both CaE and ChE to ascertain if in vitro sensitivity of CaE and ChE predicted the pattern of inhibition seen after in vivo dosing with chlorpyrifos (CPF; 80 mg/ kg, p.o.) in male or female adult Long-Evans rats. For the brain, the in vitro sensitivity to CPF-oxon did predict the in vivo patterns of inhibition: In vitro, brain ChE was approximately 25 times more sensitive to the active metabolite, CPF-oxon, than brain CaE, and in vivo brain ChE was more inhibited than brain CaE. In contrast, the in vitro sensitivity of plasma ChE and CaE did not correlate well with the in vivo pattern of inhibition: In vitro, plasma ChE was approximately 6.5 times less sensitive to CPF-oxon than plasma CaE, but in vivo, plasma ChE was more inhibited than CaE. In order to understand the role of CaE in protecting the brain ChE from inhibition by CPF-oxon in vitro, adult rat striatal tissue was incubated in the presence and absence of adult rat liver tissue and IC50S of CPF-oxon were determined. The increase in the striatal CPF-oxon IC50 value noted for ChE in the presence of liver suggested that CaE was binding the CPF-oxon and limiting its access to ChE. Male liver CaE, which has the same affinity for binding CPF-oxon as female liver CaE but has twice as many binding sites, caused a greater increase in the striatal CPF-oxon ICjo than female liver, suggesting that the number of binding sites does play a role in the detoxification potential of a tissue. In summary, we found that (1) there are tissue and gender-related differences for basal ChE and CaE activity; (2) the in vitro sensitivity of CaE or ChE to CPF-oxon is highly tissue-specific; (3) the pattern of ChE and CaE inhibition after in vivo dosing with CPF is not necessarily predictable from the in vitro IC50 for these same enzymes, and (4) the number of CaE molecules may play a role in modifying the toxicity of CPF.
Chlorpyrifos (CPF) is an organophosphate insecticide known to cause acute toxicity through irreversible inhibition of acetylcholinesterase (ChE, EC 3.1.1.7), the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This leads to accumulation of acetylcholine at the cholinergic synapse that can cause various adverse pharmacological responses. Organophosphates can also bind irreversibly to other nontarget esterases, e.g., carboxylesterase (CaE, EC 3.1.1.1), without causing any obvious effects.
CaEs are thought to act as a detoxifying enzyme by decreasing the overall concentration of the organophosphate at the target enzyme site, ChE (for a review, see Maxwell, 1992b) . A quarter of a century ago, Su and co-workers noted that many organophosphate pesticides caused inhibition of liver CaE at lower dietary levels than those required to cause brain ChE inhibition (Su et al., 1971) . Since that time, many groups have investigated the possible role of CaE in antiChE toxicity. It is now clear that CaE is capable of altering the toxicity profile of many nerve agents (Clement, 1984a,b; Fonnum et al., 1985; Gupta and Dettbarn, 1987; Jimmerson et al., 1989; Purshottam and Srivastava, 1989; Clement and Erhardt, 1990; Maxwell, 1992a Maxwell, , 1987a and some anticholinesterase pesticides (e.g., Gupta and Kadel, 1989; Chambers et al., 1990; Gupta and Dettbarn, 1993) .
It is not clear, however, what factors determine how efficiently CaE in any tissue will detoxify any given antiChE pesticide. The literature proposes two main hypotheses: (1) the effectiveness of the CaE in any given tissue is primarily due to the number of CaE molecules relative to the number of pesticide molecules, i.e., what proportion of the dose can be removed by binding to CaEs (Junge and Krisch, 1975; Maxwell, 1992a) or (2) the effectiveness is determined by the affinity of the CaE for a given pesticide (Chambers et al, 1990; Chambers and Carr, 1993) . In their 1993 study comparing the toxicity profiles of three organophosphate pesticides in whole organisms, Chambers and Carr concluded that the in vitro enzyme sensitivities can predict the patterns of in vivo enzyme inhibition after exposure to these organophosphorus compounds. This deduction was based on the finding that the affinity of the liver CaE and brain ChE correlated well with the in vivo patterns of inhibition in the whole animal. These patterns of in vivo inhibition, however, could also be due to differential distribution of the organophosphate pesticide or its active metabolite in these two tissues. To examine in a systematic manner what determines CaE detoxification efficacy, one must compare the in vitro affinities with the in vivo inhibition pattern of CaE and ChE in the same tissue, which will control for differential distribution of the pesticide.
Our laboratory is interested in validating in vitro methods which will predict in vivo toxicity. If enzyme affinities predict the in vivo pattern of inhibition, there is the potential for using these affinities in human tissue to predict human susceptibility. The present study was performed using both in vivo and in vitro methods to delineate whether the in vitro sensitivity of CaE and ChE to CPF-oxon in three different tissues would predict the in vivo pattern of inhibition as proposed by Chambers and co-workers (Chambers et al, 1990; Chambers and Carr, 1993) . In the in vivo dosing experiments, both male and female rats were studied and an oral route of exposure was chosen to mimic a possible human exposure route. The specific objectives of this study were:
(1) to determine in vitro the sensitivity of brain, plasma, and liver CaE or ChE to the active metabolite CPF-oxon and then (2) to correlate these in vitro results with the pattern and time course of brain, liver, and plasma ChE and CaE inhibition after in vivo dosing with CPF.
MATERIALS AND METHODS

Chemicals
Chlorpyrifos (0,0-diethyl 0-(3,5,6-trichloro-2-pyridyl)phosphorothioate (CPF) was purchased from Chem Service (Westchester, PA, >98% pure). Chlorpynfos-oxon (CPF-oxon) was obtained from USEPA Repository (RTP, NC; >98% purity). [ 3 H]Acetylcholine iodide (ACh, sp act 93.2 mCi/ mmol) was purchased from DuPont New England Nuclear (Wilmington, DE). Phenyl saligenin phosphate (PSP) was a gift from Dr. Marion Ehrich (Division of Pharmacology/Toxicology, VA/MD Reg. College of Veterinary Med., Blacksburg, VA) which was purchased from Lark Enterprise (Webster, MA). All other chemicals used were analytical grade.
Animals and Treatment
Male and female Long-Evans hooded rats [CRL:(LE)BR] were obtained from Charles River Inc. (Raleigh, NC). Each rat was housed individually in polycarbonate cages and fed commercially available rat chow (Purina rat chow) and water ad libitum. All animal handling procedures followed N1H guidelines and were approved by the USEPA Animal Care and Use Committee. These rats were a part of a larger, collaborative experiment designed to study sex differences in responses to pesticides.
The animals were treated with either chlorpyrifos (80 mg/kg, p.o., 1 ml injection volume/kg) or com oil vehicle and sacrificed at 1,2, 3.5, 6.5, 24, 72, 168, or 336 hr (n = 5/treatment/sex/timepoint). At the time of sacrifice they were anesthetized with carbon dioxide and decapitated. Blood was collected in heparinized centrifuge tubes. The blood samples were centrifuged at 2500g for 5 nun in a Sorvall MC 12 V microcentrifuge (DuPont, Atlanta, GA) to obtain plasma. Whole brain was collected and liver was perfused with approximately 120 ml of normal saline at room temperature. Perfusion was started after the needle was inserted into the left ventricle and stopped when the liver changed color from rich red to pale brown. A piece of the perfused left liver lobe was taken and blotted using a Kimwipe. Brain and liver were stored at -80°C until time of assay. Whole brain (1:100, w/v, i.e., 1 g in 99 ml of buffer) or for the in vivo studies frontal cortex (1:50) or liver (1:5) was homogenized in 0.1 M sodium phosphate buffer, pH 8.0, containing 1% Triton X-100 on ice using a Polytron (PT 10/35, Kinematica GmbH, Switzerland) for 20 sec at setting No. 5 and assayed for liver or brain CaE or ChE activity.
Enzyme Assays
Cholinesterase. Brain, plasma, and liver cholinesterase was measured either radiometrically (Johnson and Russell, 1975) or spectrophotometrically (Ellman et al, 1961) as detailed in Nostrandt et al, 1993 . The radiometric assay was used to measure liver ChE activity because the high glutathione content in this tissue increases absorbance at 412 nm above that which can be measured accurately by the spectrophotometer. Briefly, the radiometric assay was performed by incubating liver tissues (20 fi\, 1:5, w/v, at 26°C) with [ 3 H]channel efficiency of »25%. The Ellman assay for microtiter plate was performed for brain (5 fi\ of 1:50, w/v, or 10 [i\ of 1:100) or plasma (5 /A) using acetylthiocholine as a substrate (1 mM final concentration). Change in optical density was noted every 10 sec for 5 min at 412 nm. Preliminary experiments were conducted to define conditions for incubation time and tissue concentration required for linear rates of substrate hydrolysis for both the assays.
Carboxylesterase assay. Carboxylesterase activity was determined essentially by the method of Clement and Erhardt, 1990 , adapted in our laboratory for microassay with the total reaction volume of 200 y\. The assay was performed in 96-well, U-bottom polystyrene microtiter plates (Co-star, Cambridge, MA) using a Thermomax microtiter plate reader (Molecular Devices Inc., Menlo Park, CA) which maintained temperature at 26°C. Tissues (20 /il of either brain, 1:100, w/v, or liver, 1:1000, w/v, or 10 /il of 1:10 plasma) was diluted with 80 /il of Tris buffer (20 mM, pH 8.0) to which 100/il of the substrate/7-nitrophenyl acetate (PNPA, 0.88 mM) was added. Ethylene glycol-bis(j9-amino ethyl ether)-A',A f ,W,A r -tetraacetic acid (EGTA, 1 mM final concentration) was added to the plasma samples to inhibit Ca 2+ -dependent hydrolases (i.e., A-esterases). Brain and liver showed no A-esterase activity at that tissue concentration. Incubation time and tissue concentration were chosen to produce linear rates of substrate hydrolysis. The increase in absorbance at 405 nm was read for three 2-min intervals (with a reading every 10 sec) from the time the substrate was added using the computer software Softmax (Molecular Devices Inc.). Experiments were performed to obtain optimum substrate concentration by incubating the tissue with different concentrations of substrate and measuring the change in CaE activity in mOD/min (Fig. 1) . A standard curve of pnitrophenol was constructed by adding increasing amounts of />-nitrophenol (nmol) and measuring die increase in optical density at 405 nm. Reaction wells containing everything except the tissue were run simultaneously to account for the spontaneous hydrolysis of PNPA. Our validation experi-10 100 1000 Concentration of PNPA (pM) FIG. 1. Substrate concentration curve for CaE assay using the substrate p-nitrophenyl acetate. CaE activity is expressed as change in mOD/min. (Inset) Standard curve for p-nitrophenol; change in optical density of increasing amounts of p-nitrophenol was measured at 405 nm. ments indicated that ChE does not hydrolyze PNPA. CaE activity was calculated as nanomoles of /7-nitrophenol produced/rmn by dividing the readings obtained (mOD/min) by the slope of the />-nitrophenol standard curve (21.5 mOD/nmol p-nitrophenol; (Fig. 1, inset) . In another experiment, plasma CaE activity was measured using <*-naphthyl acetate (u-NA, 1 mM) as a substrate in a final reaction volume of 1 ml. Generation of ^-naphthol was measured at 302 nm using a Beckman DU-70 spectrophotometer.
Determination of IC X of Chlorpyrifos-oxon for Brain, Plasma, or Liver ChE and CaE
To obtain comparable IC^s for CPF-oxon for both ChE and CaE in brain, plasma, and liver, the preincubation time with the oxon (30 min), subsequent incubation time with the substrate (5 min), and the ratios of tissue, buffer, or substrate added in the reaction well were the same for both CaE and ChE assays in the tissues. Validation experiments demonstrated that the radiometric or spectrophotometric assays yielded comparable results.
Brain, plasma, or liver ChE IC^for chlorpyrifos-oxon.
Brain (10 /xl, 1:100, w/v) or plasma (5 (A) was preincubated with different concentrations of CPF-oxon for 30 min at 26°C and assayed for residua] amounts of ChE activity using the spectrophometric method. Ca 2+ -dependent hydrolases (e.g., A-esterases) were inhibited by including EGTA (1 mM final concentration) in the preincubation mixture. Perfused liver homogenate (20 /il, 1:5, w/v) was preincubated with the same concentration of EGTA (1 mM final concentration) and different concentrations of CPF-oxon for the same amount of time at the same temperature as that above, and the residual ChE was measured radiometrically.
Brain, plasma, or liver CaE IC M for chlorpyrifos-oxon.
Brain homogenate (20 ii\, 1:100, w/v), plasma (10 /il, 1:20, w/v) or perfused liver homogenate (20 /il, 1:1000, w/v) was preincubated with appropriate concentrations of CPF-oxon and EGTA (1 mM final concentration) for 30 min at 26°C. Residual amounts of CaE activity were measured as described above. Validation experiments showed that a 1 mM concentration of EGTA did not inhibit either ChE or CaE activity.
Iso-OMPA was not added to the reaction mixtures because at 100 /JM (>90% inhibition of BuChE activity), it also inhibits approximately 50* of CaE activity ( Fig. 2A) . Liver tissue at 1:1000 (w/v) dilution contains minimal amount of BuChE activity, however.
Determination of ChE or CaE IC^s of chlorpyrifos-oxon with brain or brain + liver homogenate mixture. In another group of experiments, the IC50 for CPF-oxon was estimated for brain tissue in the presence and absence of liver tissue to investigate the role of liver CaE in "protecting" the brain ChE activity from inhibition by CPF-oxon.
Rat striatum (5 fil, 1:100) or striatum + male or female liver homogenates (5 /JI each, 1:100) were mixed with 40 /jl of preincubation mixture containing 1 mM EGTA and different concentrations of CPF-oxon. In this (BuChE) or CaE activity in the liver following incubation with increasing concentrations of iso-OMPA. Liver homogenate was incubated with indicated concentrations of iso-OMPA for 30 min at 26°C, and residual ChE or CaE activity was measured. Data represent percentages of control values (means ± SEM, n = 3/assay). (B) Inhibition of ChE or CaE activity in the liver following incubation with increasing concentrations of PSP. Liver homogenate was incubated with different concentrations of PSP for 1 hr at 26°C and residual ChE or CaE activity was measured. Data represent percentages of control values (means ± SEM, n = 3/assay). If no standard error bars are apparent, then the variability was less than the symbol size. mixture, liver contributed most of the CaE activity (>95%) and all of the ChE activity was due to the striatal tissue. The tissues were incubated for 1 hr at 26°C before addition of acetylthiocholine (1 rriM final concentration). The residual ChE activity was measured spectrophotometrically as mentioned above. CaE activity was also measured on the same tissue samples keeping all the conditions exactly the same as above and using PNPA (0.88 mM final concentration) as the substrate.
To investigate the contribution of protein content of the liver tissue sample in the shift of the striatum ChE IC50, striatum was mixed with bovine serum albumin fraction V (BSA, >96% albumin). Five microliters of a 1:100 w/v liver homogenate was used in the preceding assays; assuming that 95% of the wet weight of liver tissue is water and 5% is protein and lipid, a 5 mg/10 ml stock solution of BSA was made and 5 [A of it was used in the assay. Thus, striatum (5 fA, 1:100) and BSA (5 /il of the stock solution) were preincubated with 1 mM EGTA and different concentrations of CPF-oxon, and residual ChE was measured as described above.
To eliminate the contribution of liver CaE activity from the mixture of stnatum and liver, the CaE inhibitor PSP (30 nM) was added to the mixture and IC50S were estimated. Preliminary experiments determined the concentration of PSP that inhibits CaE but not ChE activity, as shown in Fig. 2B . Residual amounts of ChE were measured by the above mentioned method.
Calculation of IC X Values
Respective concentrations of CPF-oxon that caused either ChE or CaE inhibition were plotted logarithmically against the percentage of control ChE or CaE inhibition. Only the linear portions of the curves were used for IC50 determination. ICjo values were calculated using the computer program Pharmacologic Calculation Program (Tallarida and Murray, 1981) .
Statistics
Brain, plasma, or liver ChE and CaE were compared between control and treated groups at different time points by factorial analysis of variance (ANOVA) followed by the Student Newman-Keuls (SNK) test using SigmaStat (1992) . IC50 values were calculated for each sample and mean ± SEM was determined. Significant differences between mean IC50 values were analyzed by paired t test (SigmaStat, 1992) .
RESULTS
Interestingly, comparison of the control levels of enzyme activity indicated that there were some sex-related differences in the activity of basal CaE and ChE in the brain, plasma, and liver of Long-Evans rats (Table 1) . While there was no difference in ChE activity in the male and female brain, female plasma had approximately 2.5 times more ChE activity than male plasma, whereas male liver ChE activity had approximately 30% more ChE activity than that in the females. Male liver CaE-specific activity was approximately twice that of the female liver, whereas the CaE activity in the brain of males was approximately 15% less than the females (see Table 1 ).
[ CJO Values after in Vitro Incubation of Brain, Plasma, or Liver Tissues with Chlorpyrifos-oxon
In vitro IC50 studies were performed to determine the inherent sensitivities of CaE and ChE in the male rat brain, plasma, or liver to CPF-oxon. Tissues were incubated with Liver ChE appears to be about 650 times less sensitive than brain ChE to the inhibition by CPF-oxon (IC50, 1930 ± 250 and 3.01 ± 0.28 nM, respectively; Fig. 3A ). In contrast, liver CaE appears to be about 90 times more sensitive to the inhibition by CPF-oxon compared to brain CaE (IC M : 0.89 ± 0.23 and 79.4 ± 19.6 nM, respectively; Fig. 3B ). Brain CaE shows a definite biphasic response, suggesting that there may be two or more isoforms of the enzyme in the brain with different sensitivities to CPF-oxon. The brain and plasma IC50 was calculated by taking the response of the first part (i.e., most sensitive) of the curve. Interestingly, these in vitro studies showed that plasma CaE is approximately 10 times more sensitive to inhibition by CPF-oxon compared to plasma ChE. The rank order for CaE sensitivity to CPF-oxon between the tissues was liver > plasma » brain and that for ChE was reversed: brain > plasma > liver.
ChE and CaE Inhibition after in Vivo Exposure to Chlorpyrifos
In vivo exposure to chlorpyrifos caused significant reduction in brain, plasma, and liver ChE activity (Figs. 4A-4C) . Initially (i.e., 1-24 hr after treatment), both male and female brain ChE activity was more inhibited (50-80%) than CaE activity (30-40%). The recovery of brain ChE activity began by 24 hr (male) and 72 hr (female) after dosing. Brain CaE activity did not recover to control levels in either sex during the 2-week sampling period (Fig. 4A) . Similar to the brain, plasma ChE activity (Fig. 4B ) was more inhibited (80-95%) at earlier time points (1-24 hrs after treatment) than CaE activity (50-60%). Both enzyme activities recovered to control levels by 2 weeks after treatment. In the liver (Fig. 4C) , both ChE and CaE activities 
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FIG. 3. (A)
In vitro inhibition of brain, plasma, or liver ChE activity by CPF-oxon. Brain, plasma, and liver homogenates were incubated with varying concentrations of CPF-oxon for 30 min at 26°C and residual ChE activity was measured (see Materials and Methods for details of incubation). ICJO values for brain, plasma, and liver ChE were expressed as means ± SEM of three tissue samples from different animals. (B) In vitro inhibition of brain, plasma, or liver CaE activity by CPF-oxon. Brain, plasma, and liver homogenates were incubated with varying concentrations of CPFoxon for 30 min at 26°C and residual CaE activity was measured. ICJO values for brain, plasma, and liver CaE were represented as means ± SEM of three tissue samples from different animals. ICjo values for brain and plasma CaE were calculated using the most sensitive part of the curve, from 0.75 to 75.0 nM and 10 to 100 nM CPF-oxon concentration, respectively. were extensively inhibited >90% from 1 to 24 hr after treatment. Both male and female liver ChE activity was completely recovered by 1 week after treatment, whereas liver CaE activity was still 30-10% inhibited at 2 weeks in both sexes. In general, females exposed to chlorpyrifos showed a similar degree of maximal inhibition of both ChE and CaE activity in the liver and brain as the males; however, maximum inhibition and recovery of enzyme activity occurred at a later time point than those in males. There is a good correlation between the in vitro sensitivity to CPF-oxon and in vivo inhibition of ChE and CaE activity in the brain by CPF: The in vitro IC50 determinations indicated that brain ChE is approximately 25 times more sensitive to CPF-oxon than is brain CaE activity, and after in vivo dosing with chlorpyrifos, the brain ChE is more inhibited than brain CaE activity. In the plasma, however, a similar correlation does not appear to hold true; i.e., the plasma ChE is more inhibited than the plasma CaE following in vivo exposure although the sensitivities in vitro are reversed. Though the sensitivities of ChE and CaE to the CPF-oxon are reversed in the liver compared to the brain (liver CaE is more sensitive to CPF-oxon inhibition), predicting the correlation is difficult due to extremely high inhibition of both liver ChE and CaE activities.
IC S0 Values after in Vitro Incubation of Brain or Brain + Liver Tissues with Chlorpyrifos-oxon
The previous in vitro experiments have shown that liver CaE is approximately three times more sensitive to inhibition by CPF-oxon as compared to brain ChE, but it is unclear whether liver CaE can protect the brain ChE from inhibition by CPF-oxon in the rat. Because the in vivo experiments were inconclusive on that point, in vitro experiments were designed to test empirically whether liver CaE could lessen the impact of CPF-oxon on rat brain ChE. This was accomplished by determining brain ChE IC30S toward CPF-oxon in the presence and absence of liver tissue. A test system was designed where the ChE activity was contributed by the rat brain tissue, the CaE activity was contributed by the rat liver tissue, and there was very little or no BuChE activity. Striatum contains high ChE activity with little or no BuChE activity. Liver was the source for >95% CaE activity. A mixture of equal amounts of striatum and male or female liver was used for the assay. ICjo values were determined. The IC50 value for striatum alone was 1.43 ± 0.05 nM. Upon addition of equal amounts of male or female liver to the striatum, the IC50 value was increased fourfold in male and about threefold in female liver tissues (Fig. 5A ). Male and female liver have identical CaE affinity toward CPF-oxon (IC50S: 5.65 ± 1.69 and 4.09 ± 0.82 nM, respectively).
Addition of the liver to striatum may increase the protein content or the number of nonspecific binding sites in the the ChE IC30 of the striatum + liver mixture to chlorpyrifos-oxon. Striatum and striatum + liver homogenate were incubated with varying concentrations of CPF-oxon in presence or absence of PSP for 1 hr at 26°C and residual ChE activity was measured. Data represents percentages of control values (mean ± SEM of three separate striatum mixed with diree separate liver samples). If no standard error bars are apparent, the margin of variability was less than the symbol size. Asterisks indicate significant differences between the two values (p < 0.05).
mixture. To determine the contribution of these factors, an equivalent amount of bovine serum albumin (BSA) was added to striatum and IC50S were determined. There were no significant differences between the IC50 values of striatum with or without BSA (Fig. 5B) , indicating that nonspecific binding sites probably do not play a major role in changing the ICso values.
If CaE was responsible for the change in ICjo values of striatum in the presence and absence of liver tissue, then inhibition of the CaE activity in the mixture of striatum and liver tissue should give ICso values comparable to those measured with striatum alone. PSP (30 nM) can preferentially inhibit >80% of liver CaE activity (Fig. 2B) . Incubation of striatum with CPF-oxon in the presence of PSP did not alter the sensitivity of ChE to CPF-oxon (Fig. 5C ). The addition of PSP to the striatum + liver mixture significantly lowered the ICM values (Fig. 5C ), indicating that liver CaE, specifically, may play a role in modulating the effective concentration of CPF-oxon in this system.
DISCUSSION
The patterns of CaE and ChE activity in control animals showed tissue-and gender-related differences. In control animals, ChE activity was higher in the brain compared to the plasma or liver (Table 1) . Gender-related differences in ChE activity were observed in the plasma and liver. We found, as have others (McCollister et al, 1974; Benke and Murphy, 1975; Stem et al, 1985a ) that females have more plasma ChE activity than males. In contrast, female liver ChE activity is slightly less than male liver ChE activity. The pattern of basal CaE activity was different from the ChE pattern (Table 1) . There are multiple forms of CaE in the liver (Junge and Krisch, 1975; Morgan et al., 1994) and plasma (Tsujita and Okuda, 1983) . CaEs are also substratespecific (Tsujita and Okuda, 1983; Stem et al, 1985a,b; Fonnum et al, 1985; Shirai et al, 1985) . In the majority of our experiments, we have defined CaE using PNPA as a substrate. As observed by other investigators (Tsujita and Okuda, 1983; Maxwell et al, 1987a; Chambers and Carr, 1993) , the liver possess much higher CaE activity compared to brain or plasma. Gender-related differences in liver CaE activity were observed: The male CaE activity is almost twice that of the female, similar to the pattern reported by Morgan and co-workers (1994) .
There were considerable differences in the sensitivity of both ChE and CaE to CPF-oxon in the three tissues as defined by the 30-min CPF-oxon IC50 (Fig. 3) . Utmost care was taken to obtain comparable IC50 values in brain, plasma, and liver [tissue concentration may affect CPF-oxon ICJO values unless extrinsic factors are eliminated during the assay (Mortensen et al, 1997) ]. As noted by Chambers and co-workers (1990) , liver CaE was about three times more sensitive to CPF-oxon inhibition than brain ChE. Tissuewise comparison of the IC50 values indicate that liver CaE (0.89 nM) and brain ChE (3.07 nM) are much more sensitive to CPF-oxon than plasma CaE (42.3 nM), brain CaE (79.4 nM), plasma ChE (273.4 nM), or liver ChE (1930 nM) . If the in vivo inhibition spectrum was solely dependent on these in vitro sensitivities, then the profile after in vivo dosing would be liver CaE inhibition > brain ChE inhibition > plasma CaE inhibition > brain CaE inhibition, etc., which is not the case (see Fig. 4) . Obviously, the first confounding factor in that simplistic scenario should be the fact that the concentration of CPF-oxon is not the same in each tissue after an oral dose of CPF. One would assume that the liver concentration would be higher than the plasma, which in turn would be more than the brain concentration. In order to control for this differential distribution one could just compare the relative sensitivity of the ChE vs CaE in a given tissue with the assumption being that both these enzymes are exposed to the same concentration of CPF-oxon in any one tissue (see below).
Given that brain ChE is 25 times more sensitive than brain CaE to inhibition in vitro by CPF-oxon (Fig. 3) , it would be expected that in vivo dosing would produce more inhibition of brain ChE than CaE. That was exactly the pattern that was noted (Fig. 4A) . Therefore, in brain tissue, the in vitro sensitivity to CPF-oxon predicted the in vivo inhibition after CPF administration. That, however, did not appear to be case for either liver or plasma. In the liver, the biggest discrepancy between the ICSQS was noted: liver ChE was about 2000 times less sensitive to CPF-oxon inhibition than CaE. Following the in vivo dosing, however, no clear conclusion may be drawn regarding the predictability of the in vitro measurements as both liver enzymes were maximally inhibited (Fig. 4C) . This high degree of in vivo inhibition for both enzymes is probably a result of the high concentration of CPF-oxon in the liver after this oral dose (Sultatos et al, 1984 (Sultatos et al, , 1985 . In the plasma, ChE was about six times less sensitive to inhibition by CPF-oxon than plasma CaE (Fig. 3) , so one would predict more inhibition of plasma CaE than ChE after in vivo dosing, which was not the case (Fig. 4B) . Therefore, it is clear that the in vitro sensitivity of these enzymes does not always predict the in vivo pattern of inhibition for a given tissue.
Consequently, empirical evidence indicates that the detoxification potential of any tissue is not solely a function of the inherent affinity of the CaE for the organophosphate (i.e., IC50; discussed above). The detoxification potential should also be dependent on the number of molecules available for binding CPF-oxon. Because CaE detoxifies stoichiometrically (not by hydrolysis), the number of molecules available for binding the CPF-oxon is very important. When at-tempting to rectify the in vivo inhibition profiles with the in vitro profiles, the number of molecules of each enzyme, ChE and CaE, must be taken into account. In both the plasma and liver, it is known that the number of CaE molecules far exceeds the number of ChE molecules: 3700 and 51,000 times greater, respectively (Maxwell et al., 1987a) . Therefore, even if, in a given tissue, the sensitivity of the CaE equals or may be more sensitive than the ChE to inhibition by CPF-oxon, the percentage inhibition of CaE may be less than the ChE inhibition, solely because a much higher number of molecules of CaE must be inhibited in order to change the total activity compared to ChE. For example, in the plasma, CPF-oxon has to bind to about 3700 molecules of CaE to every 1 of ChE just to maintain the same degree of inhibition of both enzymes. This means that the CaE of a given tissue could be "protecting" the ChE of that same tissue even if the CaE percentage of inhibition is less than the percentage of inhibition for the ChE. Moreover, our data presented in Fig. 5A showing that male liver is more efficacious than female liver at protecting brain ChE is another example of the importance of number of binding sites. In this case both male and female liver have the identical CaE affinity towards CPF-oxon, but the male liver has twice as much CaE, which correlates well with its protecting ability.
Another factor which may contribute to the discrepancy between the in vitro sensitivity and the in vivo pattern of inhibition is the heterogeneity of the carboxylesterases, especially with regard to inhibition by CPF-oxon. In other words, there might be a subset of CaE activity that is highly resistant to CPF-oxon inhibition; for example, our IC50 profiles indicate that there may be an isoform of CaE that may be insensitive to inhibition by the oxon, as some residual CaE activity (10-25%) remained even at high CPF-oxon concentrations in both plasma and brain (Fig. 3B ). Similar observations have been made with paraoxon (Carrington and Abou Donia, 1985; Heymann et al., 1993) and mipafox (Novak and Padilla, 1986) , which exhibit selective sensitivity toward a particular isoform of CaE in a given tissue. There are reports that another CaE substrate, a-NA, is a more specific substrate for the subclass of carboxylesterases which have a high affinity for organophosphates (Dettbarn and Yang, 1996) ; therefore, both the in vivo and in vitro determinations of CaE activity were repeated using this substrate to determine if the in vitro data would be more predictive of the in vivo pattern of inhibition. Although there was slightly more inhibition of the ac-NA-hydrolyzing CaE (compared to the PNPA-hydrolyzing CaEs) in rat plasma after in vivo dosing with CPF, ChE activity in the plasma was still more inhibited than CaE activity at earlier timepoints. Similar to that observed with PNPA, the inherent sensitivity of this particular isoform of CaE to CPF-oxon is greater than the ChE (plasma CaE CPF-oxon IC50 using «-NA = 141.63 ± 44 nM). Therefore, the discrepancy in the plasma data cannot be explained by an isoform difference. Possibly, this resistant subset of PNPA-hydrolyzing activity may be C-esterases (acetylesterases; EC 3,1.1.6), which are capable of hydrolyzing PNPA and are resistant to inhibition by organophosphate compounds (Junge and Krisch, 1975) .
To study the possible intertissue protection capabilities of CaE, we designed an in vitro experiment patterned after that of Chambers and co-workers (1990) . Our mixing experiments are basically an elaboration of their method, but we used rat brain instead of bovine brain (rat brain ChE is 2.5 times more sensitive to CPF-oxon than bovine brain; Chambers et al., 1990) , exposed both tissues to the CPFoxon simultaneously (to increase the "competition" between the tissues for the CPF-oxon), and performed control experiments to add evidence that it is the CaE activity and not other binding sites that is shifting the CPF-oxon IC50 for the brain tissue. We wanted specifically to examine the role of male and female rat liver CaE activity in protecting the rat brain ChE from inhibition by CPF. Among all three of the tissues studied, liver had the largest detoxification potential, because it had the lowest IC^ and the highest concentration of CaE molecules (Maxwell, 1987a) as well as the largest difference in male and female activity. In our system the presence of liver homogenate caused a parallel shift to the right for the striatal ChE IC50 curves, indicating that the liver tissue was binding the oxon, i.e., more of the oxon was required to produce the same effect. There was a greater increase in the striatal ChE ICjo curve in the presence of male liver compared to the female liver tissue. This correlates well with the number of CaE binding sites in the tissue (male liver has about twice the CaE activity as female liver and presumably the turnover number is the same in both sexes) and not with inherent sensitivity of the CaE (male and female liver CaE CPF-oxon IC50S are identical). Additional experiments established that the IC50 shifts were specifically due to the presence or absence of CaE activity (Fig. 5C) and not due to nonspecific binding sites (Fig. 5B) . In summary, these data indicate that sensitivity of striatal ChE to CPF can be altered upon addition of equivalent amounts of liver tissue with different degrees of CaE activity. The CaEs appear to bind up the CPF-oxon, therefore requiring more of it to produce similar degrees of AchE inhibition. Upon eliminating >80% of the liver CaE activity, most of the effect is reversed.
Taken together, these results indicate that (1) there are tissue and gender-related differences for basal ChE and CaE activity (Table 1) ; (2) both ChE and CaE display tissuespecific sensitivity toward CPF-oxon with IC30S varying as much as three orders of magnitude (Fig. 3) ; (3) in agreement with Chambers and co-workers (1990) and Chambers and Carr (1993) , it is likely that liver CaE may perform a detoxi-fication role in CPF toxicity; and (4) the pattern of ChE and CaE inhibition after in vivo dosing with CPF is not necessarily predictable from the in vitro IC50 for these same enzymes (Fig. 4) . Therefore, it appears that both affinity and number of CaE binding sites play an important role in determining effectiveness of anticholinesterase detoxification. In tissues where there are comparable numbers of CaE to ChE binding sites, like brain, in vivo inhibition profiles appear to reflect the in vitro sensitivity of these enzymes; however, in tissues such as liver and plasma, where there are thousands of CaE molecules to each ChE molecule, affinity alone does not account for the in vivo inhibition patterns.
It must be noted that the modulation of toxicity by any pharmacokinetic factor is exquisitely compound-specific. One consideration is the ratio of the number of molecules of the toxic compound to the available binding sites of CaE; in fact, Maxwell has clearly demonstrated this compound specificity in relation to the potency of the compound (Maxwell, 1992a) . Interwoven with the question of binding sites is the question of affinity of a given compound for both the target and detoxification enzymes, which obviously are also compound-specific. One must, therefore, be cautious about extrapolating the present results and conclusions to other organophosphate compounds.
